Leukotrienes increase levels of prostanoids in cerebrospinal fluid in piglets.

D. Busija,C. Leffler

DOI: https://doi.org/10.1016/0090-6980(86)90091-2

1986-12-01

Prostaglandins

Abstract:

What problem does this paper attempt to address?

The determination of mercury in water samples from the environment by neutron activation analysis.

H. A. van der Sloot,H. A. Das

DOI: https://doi.org/10.1016/S0003-2670(01)85460-X

IF: 6.911

1974-12-01

Analytica Chimica Acta

Abstract:
Writing to be searched: A workshop on document creation principles

M. Lesk

DOI: https://doi.org/10.1145/16287.16288

Abstract:Attendance will be limited to 75; there will be no formal proceedings, but a report will be written for some ACM publication; a number of prominent people (Karen Sparck Jones, David McDonald, Donald Walker, Patricia Wright, etc.) have indicated interest in attending. Comments on the workshop, or indications of interest, are welcome. Please notify the chair at: bellcore!lesk, or lesk%bellcore@csnet-relay, or (if you have current routing tables) lesk@bellcore. Phone: 201-829-4070.
Azithromycin in viral infections

Madeleine E Oliver,Timothy S C Hinks

DOI: https://doi.org/10.1002/rmv.2163

Abstract:Azithromycin (AZM) is a synthetic macrolide antibiotic effective against a broad range of bacterial and mycobacterial infections. Due to an additional range of anti-viral and anti-inflammatory properties, it has been given to patients with the coronaviruses SARS-CoV or MERS-CoV. It is now being investigated as a potential candidate treatment for SARS-CoV-2 having been identified as a candidate therapeutic for this virus by both in vitro and in silico drug screens. To date there are no randomised trial data on its use in any novel coronavirus infection, although a large number of trials are currently in progress. In this review, we summarise data from in vitro, murine and human clinical studies on the anti-viral and anti-inflammatory properties of macrolides, particularly AZM. AZM reduces in vitro replication of several classes of viruses including rhinovirus, influenza A, Zika virus, Ebola, enteroviruses and coronaviruses, via several mechanisms. AZM enhances expression of anti-viral pattern recognition receptors and induction of anti-viral type I and III interferon responses. Of relevance to severe coronavirus-19 disease (COVID-19), which is characterised by an over-exuberant innate inflammatory response, AZM also has anti-inflammatory properties including suppression of IL-1beta, IL-2, TNF and GM-CSF. AZM inhibits T cells by inhibiting calcineurin signalling, mammalian target of rapamycin activity and NFκB activation. AZM particularly targets granulocytes where it concentrates markedly in lysosomes, particularly affecting accumulation, adhesion, degranulation and apoptosis of neutrophils. Given its proven safety, affordability and global availability, tempered by significant concerns about antimicrobial stewardship, there is an urgent mandate to perform well-designed and conducted randomised clinical trials.
Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters

Shuofeng Yuan,Runming Wang,Jasper Fuk-Woo Chan,Anna Jinxia Zhang,Tianfan Cheng,Kenn Ka-Heng Chik,Zi-Wei Ye,Suyu Wang,Andrew Chak-Yiu Lee,Lijian Jin,Hongyan Li,Dong-Yan Jin,Kwok-Yung Yuen,Hongzhe Sun

DOI: https://doi.org/10.1038/s41564-020-00802-x

IF: 28.3

2020-10-07

Nature Microbiology

Abstract:SARS-CoV-2 is causing a pandemic of COVID-19, with high infectivity and significant mortality<sup><a href="/articles/s41564-020-00802-x#ref-CR1">1</a></sup>. Currently, therapeutic options for COVID-19 are limited. Historically, metal compounds have found use as antimicrobial agents, but their antiviral activities have rarely been explored. Here, we test a set of metallodrugs and related compounds, and identify ranitidine bismuth citrate, a commonly used drug for the treatment of <i>Helicobacter pylori</i> infection, as a potent anti-SARS-CoV-2 agent, both in vitro and in vivo. Ranitidine bismuth citrate exhibited low cytotoxicity and protected SARS-CoV-2-infected cells with a high selectivity index of 975. Importantly, ranitidine bismuth citrate suppressed SARS-CoV-2 replication, leading to decreased viral loads in both upper and lower respiratory tracts, and relieved virus-associated pneumonia in a golden Syrian hamster model. In vitro studies showed that ranitidine bismuth citrate and its related compounds exhibited inhibition towards both the ATPase (IC<sub>50</sub> = 0.69 µM) and DNA-unwinding (IC<sub>50</sub> = 0.70 µM) activities of the SARS-CoV-2 helicase via an irreversible displacement of zinc(<span class="u-small-caps">ii</span>) ions from the enzyme by bismuth(<span class="u-small-caps">iii</span>) ions. Our findings highlight viral helicase as a druggable target and the clinical potential of bismuth(<span class="u-small-caps">iii</span>) drugs or other metallodrugs for the treatment of SARS-CoV-2 infection.

microbiology
Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease

Janis Kay Shute

DOI: https://doi.org/10.3390/ph16040584

IF: 4.6

2023-04-14

Pharmaceuticals

Abstract:Unfractionated heparin has multiple pharmacological activities beyond anticoagulation. These anti-inflammatory, anti-microbial, and mucoactive activities are shared in part by low molecular weight and non-anticoagulant heparin derivatives. Anti-inflammatory activities include inhibition of chemokine activity and cytokine synthesis, inhibitory effects on the mechanisms of adhesion and diapedesis involved in neutrophil recruitment, inhibition of heparanase activity, inhibition of the proteases of the coagulation and complement cascades, inhibition of neutrophil elastase activity, neutralisation of toxic basic histones, and inhibition of HMGB1 activity. This review considers the potential for heparin and its derivatives to treat inflammatory lung disease, including COVID-19, ALI, ARDS, cystic fibrosis, asthma, and COPD via the inhaled route.

pharmacology & pharmacy,chemistry, medicinal
Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function in Patients with Covid-19 Pneumonia

Li Ma,Yanwu Zeng,Bing Zhao,Lili Xu,Jian Li,Tongyu Zhu,Enqiang Mao

DOI: https://doi.org/10.21203/rs.3.rs-101402/v1

2020-01-01

Abstract:Abstract Background Coronavirus disease 2019 (Covid-19) remains a serious health threat worldwide. It is crucial to explore effective treatment measures that reduce mortality. Our aim was to investigate whether low molecular weight heparin (LMWH) can reduce organ injury in patients with Covid-19 pneumonia. Methods A retrospective study was conducted at the Shanghai Public Health Clinical Center. We initiated a LMWH protocol from January 18th 2020. LMWH was injected subcutaneously at 4100U per day until the D-dimer(DD) level returned to normal, or 5-7 days after admission, whichever occurred first. Admitted patients who received LMWH between January 18th and February 17th 2020 were assigned to the LMWH group. Patients admitted between January 18th and February 17th who did not receive LMWH anticoagulant therapy were the control group. All patients in both groups were aged >18 years, were not pregnant, had no tumors and were in accordance with the following inclusion criteria: 1) DD increased on admission; 2) Body mass index(BMI) >30; 3) History of diabetes. The exclusion criteria were: 1) Platelets <30x10 9 /L or fibrinogen <150 mg/dL; 2) Pregnancy and lactation; 3) Presence of blood system diseases; 4) Immunosuppression; 5) Diseases with a potential risk of bleeding; 6) Receiving anticoagulant drugs or antiplatelet drugs during treatment. General clinical information, indicators for renal function, arterial blood gas analyses and blood lactic acid content were recorded in the two groups 0 (Day 0), 3 (Day 3), 7 (Day 7), and 11 (Day 11) and 15 (Day 15) days after admission. Results There were 48 patients in the LMWH group and 74 patients in the control group. General information, including age, gender, co-existing diseases and onset-to-admission time in both groups was similar. Compared to the control group, LMWH treatment improved the estimated glomerular filtration rate (eGFR) reduced the serum creatinine level (Scr), blood urea nitrogen (BUN)，arterial blood carbon dioxide partial pressure (PaCO2) and arterial blood lactic acid content. However, LMWH treatment reduced arterial oxygen partial pressure (PaO2) and arterial oxygen saturation (SaO2). Conclusion LMWH might be beneficial to improve renal function, CO2 discharge and microcirculation during the early phase of Covid-19 patients . Further randomized controlled trials(RCTs) are warranted in order to further investigate this issue. Trial registration ChiCTR, ChiCTR2000034796. Registered 19 July 2020 - Retrospectively registered, http:// www. chictr.org.cn/listbycreater.aspx.
Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin

Xiaohong Du,Xiangyang Zuo,Fang Meng,Chenfeng Han,Wei Ouyang,Yu Han,Yayun Gu,Xin Zhao,Feng Xu,Frank Xiaofeng Qin

DOI: https://doi.org/10.1111/cpr.12953

IF: 8.755

2020-11-19

Cell Proliferation

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>Using strategy of drug repurposing, antiviral agents against influenza A virus (IAV) and newly emerging SARS‐coronavirus 2 (SARS‐CoV‐2, also as 2019‐nCoV) could be quickly screened out.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and Methods</h3><p>A previously reported engineered replication‐competent PR8 strain carrying luciferase reporter gene (IAV‐luc) and multiple pseudotyped IAV and SARS‐CoV‐2 virus was used. To specifically evaluate the pH change of vesicles containing IAV, we constructed an A549 cell line with endosomal and lysosomal expression of pHluorin2.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Here, we identified azithromycin (AZ) as an effective inhibitor against multiple IAV and SARS‐CoV‐2 strains. We found that AZ treatment could potently inhibit IAV infection in vitro. Moreover, using pseudotyped virus model, AZ could also markedly block the entry of SARS‐CoV‐2 in HEK293T‐ACE2 and Caco2 cells. Mechanistic studies further revealed that such effect was independent of interferon signalling. AZ treatment neither impaired the binding and internalization of IAV virions, nor the viral replication, but rather inhibited the fusion between viral and vacuolar membranes. Using a NPC1‐pHluorin2 reporter cell line, we confirmed that AZ treatment could alkalize the vesicles containing IAV virions, thereby preventing pH‐dependent membrane fusion.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Overall, our findings demonstrate that AZ can exert broad‐spectrum antiviral effects against IAV and SARS‐CoV‐2, and could be served as a potential clinical anti‐SARS‐CoV‐2 drug in emergency as well as a promising lead compound for the development of next‐generation anti‐IAV drugs.</p></section>

cell biology
Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial

Vinicius Tadeu Ramos da Silva Grillo,Matheus Bertanha,Lenize da Silva Rodrigues,Marcelo Andrade de Lima,Pedro Luciano Mellucci Filho,Rafael Rahal Guaragna Machado,Edson Luiz Durigon,Nathália Dias Sertorio,Marjorie de Assis Golim,Andrei Moroz,Aline Márcia Marques Braz,Leonardo Nazário de Moraes,Marco Antonio Leite,Helena Bonciani Nader,Gustavo Constantino de Campos,Cristiane Rodrigues Guzzo Carvalho,Fábio Florença Cardoso,Angelo José Magro,Helga Caputo Nunes,Rejane Maria Tommasini Grotto,Rita de Cássia Alvarado,Maria Inês de Moura Campos Pardini,Marcone Lima Sobreira,Erika Alessandra Pellison Nunes da Costa,Alexandre Naime Barbosa,Carlos Magno Castelo Branco Fortaleza

DOI: https://doi.org/10.1038/s41598-024-70064-8

2024-08-27

Abstract:To evaluate the safety and the potential antiviral treatment of inhaled enriched heparin in patients with COVID-19. The specific objectives were to investigate the anticoagulation profile, antiviral and anti-inflammatory effects, and respiratory evolution of inhaled enriched heparin. We conducted a randomized, triple-blind, placebo-controlled Phase I/II clinical trial in hospitalized adults with COVID-19 receiving inhalation of enriched heparin or saline (placebo) every 4 h for 7 days. Among the 27 patients who completed the study, no changes in blood coagulation parameters were observed, indicating the safety of inhaled enriched heparin. The group receiving enriched heparin showed a significant reduction in the need for supplemental oxygen and improvement in respiratory parameters, such as the PaO2/FiO2 ratio. Inhalation of enriched heparin is shown to be safe and has also demonstrated potential therapeutic benefits for patients with COVID-19. These promising results justify the continuation of the study to the next phase, Phase II/III, to further evaluate the therapeutic efficacy of inhaled enriched heparin in the treatment of COVID-19-associated viral pneumonia.Trial registration: ClinicalTrials.gov. 08/02/2021. Identifier: NCT04743011.
Promising Antiviral Activity of Agrimonia pilosa Phytochemicals against Severe Acute Respiratory Syndrome Coronavirus 2 Supported with In Vivo Mice Study

Nashwah G. M. Attallah,Aya H. El-Kadem,Walaa A. Negm,Engy Elekhnawy,Thanaa A. El-Masry,Elshaymaa I. Elmongy,Najla Altwaijry,Ashwag S. Alanazi,Gadah Abdulaziz Al-Hamoud,Amany E. Ragab

DOI: https://doi.org/10.3390/ph14121313

IF: 4.6

2021-12-16

Pharmaceuticals

Abstract:The global emergence of the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has focused the entire world’s attention toward searching for a potential remedy for this disease. Thus, we investigated the antiviral activity of Agrimonia pilosa ethanol extract (APEE) against SARS-CoV-2 and it exhibited a potent antiviral activity with IC50 of 1.1 ± 0.03 μg/mL. Its mechanism of action was elucidated, and it exhibited a virucidal activity and an inhibition of viral adsorption. Moreover, it presented an immunomodulatory activity as it decreased the upregulation of gene expression of COX-2, iNOS, IL-6, TNF-α, and NF-κB in lipopolysaccharide (LPS)-induced peripheral blood mononuclear cells. A comprehensive analysis of the phytochemical fingerprint of APEE was conducted using LC-ESI-MS/MS technique for the first time. We detected 81 compounds and most of them belong to the flavonoid and coumarin classes. Interestingly, isoflavonoids, procyanidins, and anthocyanins were detected for the first time in A. pilosa. Moreover, the antioxidant activity was evidenced in DPPH (IC50 62.80 μg/mL) and ABTS (201.49 mg Trolox equivalents (TE)/mg) radical scavenging, FRAP (60.84 mg TE/mg), and ORAC (306.54 mg TE/g) assays. Furthermore, the protective effect of APEE was investigated in Lipopolysaccharides (LPS)-induced acute lung injury (ALI) in mice. Lung W/D ratio, serum IL-6, IL-18, IL-1β, HO-1, Caspase-1, caspase-3, TLR-4 expression, TAC, NO, MPO activity, and histopathological examination of lung tissues were assessed. APEE induced a marked downregulation in all inflammation, oxidative stress, apoptosis markers, and TLR-4 expression. In addition, it alleviated all histopathological abnormalities confirming the beneficial effects of APEE in ALI. Therefore, APEE could be a potential source for therapeutic compounds that could be investigated, in future preclinical and clinical trials, in the treatment of patients with COVID-19.

pharmacology & pharmacy,chemistry, medicinal
Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19

Chunlin Li,Ira Marton,Daniel Harari,Maya Shemesh,Vyacheslav Kalchenko,Michal Pardo,Gideon Schreiber,Yinon Rudich

DOI: https://doi.org/10.1021/acsbiomaterials.2c00419

2022-05-24

ACS Biomaterials Science & Engineering

Abstract:Delivering medication to the lungs via nebulization of pharmaceuticals is a noninvasive and efficient therapy route, particularly for respiratory diseases. The recent worldwide severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic urges the development of such therapies as an effective alternative to vaccines. The main difficulties in using inhalation therapy are the development of effective medicine and methods to stabilize the biological molecules and transfer them to the lungs efficiently following nebulization. We have developed a high-affinity angiotensin-converting enzyme 2 (ACE2) receptor-binding domain (RBD-62) that can be used as a medication to inhibit infection with SARS-CoV-2 and its variants. In this study, we established a nebulization protocol for drug delivery by inhalation using two commercial vibrating mesh (VM) nebulizers (Aerogen Solo and PARI eFlow) that generate similar mist size distribution in a size range that allows efficient deposition in the small respiratory airway. In a series of experiments, we show the high activity of RBD-62, interferon-α2 (IFN-α2), and other proteins following nebulization. The addition of gelatin significantly stabilizes the proteins and enhances the fractions of active proteins after nebulization, minimizing the medication dosage. Furthermore, hamster inhalation experiments verified the feasibility of the protocol in pulmonary drug delivery. In short, the gelatin-modified RBD-62 formulation in coordination with VM nebulizer can be used as a therapy to cure SARS-CoV-2.

materials science, biomaterials
Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections

Irene Rossi,Francesca Buttini,Fabio Sonvico,Filippo Affaticati,Francesco Martinelli,Giannamaria Annunziato,Diana Machado,Miguel Viveiros,Marco Pieroni,Ruggero Bettini

DOI: https://doi.org/10.3390/pharmaceutics11050203

IF: 6.525

2019-05-01

Pharmaceutics

Abstract:Tuberculosis resistant cases have been estimated to grow every year. Besides Mycobacterium tuberculosis, other mycobacterial species are responsible for an increasing number of difficult-to-treat infections. To increase efficacy of pulmonary treatment of mycobacterial infections an inhalable antibiotic powder targeting infected alveolar macrophages (AMs) and including an efflux pump inhibitor was developed. Low molecular weight sodium hyaluronate sub-micron particles were efficiently loaded with rifampicin, isoniazid and verapamil, and transformed in highly respirable microparticles (mean volume diameter: 1 μm) by spray drying. These particles were able to regenerate their original size upon contact with aqueous environment with mechanical stirring or sonication. The in vitro drugs release profile from the powder was characterized by a slow release rate, favorable to maintain a high drug level inside AMs. In vitro antimicrobial activity and ex vivo macrophage infection assays employing susceptible and drug resistant strains were carried out. No significant differences were observed when the powder, which did not compromise the AMs viability after a five-day exposure, was compared to the same formulation without verapamil. However, both preparations achieved more than 80% reduction in bacterial viability irrespective of the drug resistance profile. This approach can be considered appropriate to treat mycobacterial respiratory infections, regardless the level of drug resistance.

pharmacology & pharmacy
Using the StarT Back Tool: Does timing of stratification matter - In response to Peter Kent and Alice Kongsted.

D. Newell,J. Field

DOI: https://doi.org/10.1016/j.math.2014.11.010

2014-12-01

Manual Therapy

Abstract:
Inhalable Chitosan-Based Hydrogel as a Mucosal Adjuvant for Hydroxychloroquine in the Treatment for SARS-CoV-2 Infection in a Hamster Model

Donna Shu-Han Lin,Shian Chiuan Tzeng,Tai-Lung Cha,Chin-Mao Hung,Wen-Chin Lin,Chuen-Mi Yang,Hsuan-Ying Lu,Jia-Yu Chang,Shu-Wei Huang

DOI: https://doi.org/10.1016/j.jmii.2023.08.001

2023-08-16

Abstract:Background Effective therapy for COVID-19 remains limited. Hydroxychloroquine (HCQ) has been considered, but safety and efficacy concerns remain. Chitosan exhibits antiviral and immunomodulatory effects, yet how the combination of HCQ and chitosan performs in treating COVID-19 is unknown. Methods Male Syrian hamsters were inoculated intranasally with standardized stocks of the SARS-CoV-2 virus. Hamsters were allocated to saline (PBS), chitosan oligosaccharide (COS), HCQ, or COS+HCQ groups and received corresponding drugs. On days 1, 7, and 14 post-infection, two animals from each group were euthanized for sample collection. Viral loads were measured in lung homogenates. Biochemistry markers, cytokines, and immunoglobulins were analyzed from hamster sera. HCQ concentrations were compared between the blood, bronchoalveolar lavage, and lung tissues. All groups underwent histopathology exams of the lungs. Additional hamsters were treated with the same drugs to assess for toxicities to the heart and liver. Results Among all groups, viral loads in the COS+HCQ group were the lowest by day 8. The COS+HCQ group produced the highest interleukin (IL)-6 levels on day 4, and the highest IL-10, IgA and IgG levels on day 8. HCQ concentrations were higher in the COS+HCQ group's lungs than the HCQ group, despite having received half the dose of HCQ. Histopathology demonstrated earlier inflammation resolution and swifter viral clearance in the COS+HCQ group. There was no evidence of cardiac or hepatic injury in hamsters that received HCQ. Conclusion In hamsters infected with the SARS-CoV-2 virus, the combination of intranasal COS and HCQ was associated with increased HCQ absorption in the lungs, more effective immune responses, without increasing the risk of hepatic or cardiac injuries.

immunology,infectious diseases,microbiology
Local Delivery of Azithromycin Nanoformulation Attenuated Acute Lung Injury in Mice

Mohsen G. Alrashedi,Ahmed Shaker Ali,Osama Abdelhakim Ahmed,Ibrahim M. Ibrahim

DOI: https://doi.org/10.3390/molecules27238293

IF: 4.6

2022-11-29

Molecules

Abstract:Humanity has suffered from the coronavirus disease 2019 (COVID-19) pandemic over the past two years, which has left behind millions of deaths. Azithromycin (AZ), an antibiotic used for the treatment of several bacterial infections, has shown antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as against the dengue, Zika, Ebola, and influenza viruses. Additionally, AZ has shown beneficial effects in non-infective diseases such as cystic fibrosis and bronchiectasis. However, the systemic use of AZ in several diseases showed low efficacy and potential cardiac toxicity. The application of nanotechnology to formulate a lung delivery system of AZ could prove to be one of the solutions to overcome these drawbacks. Therefore, we aimed to evaluate the attenuation of acute lung injury in mice via the local delivery of an AZ nanoformulation. The hot emulsification–ultrasonication method was used to prepare nanostructured lipid carrier of AZ (AZ-NLC) pulmonary delivery systems. The developed formulation was evaluated and characterized in vitro and in vivo. The efficacy of the prepared formulation was tested in the bleomycin (BLM) -mice model for acute lung injury. AZ-NLC was given by the intratracheal (IT) route for 6 days at a dose of about one-eighth oral dose of AZ suspension. Samples of lung tissues were taken at the end of the experiment for immunological and histological assessments. AZ-NLC showed an average particle size of 453 nm, polydispersity index of 0.228 ± 0.07, zeta potential of −30 ± 0.21 mV, and a sustained release pattern after the initial 50% drug release within the first 2 h. BLM successfully induced a marked increase in pro-inflammatory markers and also induced histological changes in pulmonary tissues. All these alterations were significantly reversed by the concomitant administration of AZ-NLC (IT). Pulmonary delivery of AZ-NLC offered delivery of the drug locally to lung tissues. Its attenuation of lung tissue inflammation and histological injury induced by bleomycin was likely through the downregulation of the p53 gene and the modulation of Bcl-2 expression. This novel strategy could eventually improve the effectiveness and diminish the adverse drug reactions of AZ. Lung delivery could be a promising treatment for acute lung injury regardless of its cause. However, further work is needed to explore the stability of the formulation, its pharmacokinetics, and its safety.

chemistry, multidisciplinary,biochemistry & molecular biology
Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment

Pengyu Li,Jieyi Pan,Yating Dong,Yingying Sun,Yalong Wang,Kang Liao,Yili Chen,Xin Deng,Shihui Yu,Haiyan Hu

DOI: https://doi.org/10.1016/j.jconrel.2023.11.032

IF: 11.467

2024-01-01

Journal of Controlled Release

Abstract:Chronic pulmonary infection caused by Pseudomonas aeruginosa (P. aeruginosa) is a common lung disease with high mortality, posing severe threats to public health. Highly resistant biofilm and intrinsic resistance make P. aeruginosa hard to eradicate, while powerful virulence system of P. aeruginosa may give rise to the recurrence of infection and eventual failure of antibiotic therapy. To address these issues, infection-microenvironment responsive nanoparticles functioning on biofilm eradication and virulence inhibition were simply prepared by electrostatic complexation between dimethylmaleic anhydride (DA) modified negatively charged coating and epsilon-poly(l-lysine) derived cationic nanoparticles loaded with azithromycin (AZI) (DA-AZI NPs). Charge reversal responsive to acidic condition enabled DA-AZI NPs to successively penetrate through both mucus and biofilms, followed by targeting to P. aeruginosa and permeabilizing its outer/inner membrane. Then in situ released AZI, which was induced by the lipase-triggered NPs dissociation, could easily enter into bacteria to take effects. DA-AZI NPs exhibited enhanced eradication activity against P. aeruginosa biofilms with a decrease of >99.999% of bacterial colonies, as well as remarkable inhibitory effects on the production of virulence factors and bacteria re-adhesion & biofilm re-formation. In a chronic pulmonary infection model, nebulization of DA-AZI NPs into infected mice resulted in prolonged retention and increased accumulation of the NPs in the infected sites of the lungs. Moreover, they significantly reduced the burden of P. aeruginosa, effectively alleviating lung tissue damages and inflammation. Overall, the proposed DA-AZI NPs highlight an innovative strategy for treating chronic pulmonary infection.

pharmacology & pharmacy,chemistry, multidisciplinary
Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic

Mingjia Yu,Tianji Zhang,Wei Zhang,Qianyun Sun,Hongmei Li,Jin-ping Li

DOI: https://doi.org/10.3389/fmolb.2020.628551

IF: 6.113

2021-01-25

Frontiers in Molecular Biosciences

Abstract:Owing to the high mortality and the spread rate, the infectious disease caused by SARS-CoV-2 has become a major threat to public health and social economy, leading to over 70 million infections and 1. 6 million deaths to date. Since there are currently no effective therapeutic or widely available vaccines, it is of urgent need to look for new strategies for the treatment of SARS-CoV-2 infection diseases. Binding of a viral protein onto cell surface heparan sulfate (HS) is generally the first step in a cascade of interaction that is required for viral entry and the initiation of infection. Meanwhile, interactions of selectins and cytokines (e.g., IL-6 and TNF-α) with HS expressed on endothelial cells are crucial in controlling the recruitment of immune cells during inflammation. Thus, structurally defined heparin/HS and their mimetics might serve as potential drugs by competing with cell surface HS for the prevention of viral adhesion and modulation of inflammatory reaction. In this review, we will elaborate coronavirus invasion mechanisms and summarize the latest advances in HS–protein interactions, especially proteins relevant to the process of coronavirus infection and subsequent inflammation. Experimental and computational techniques involved will be emphasized.

biochemistry & molecular biology
Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin

Courtney J. Mycroft-West,Dunhao Su,Isabel Pagani,Timothy R. Rudd,Stefano Elli,Neha S. Gandhi,Scott E. Guimond,Gavin J. Miller,Maria C. Z. Meneghetti,Helena B. Nader,Yong Li,Quentin M. Nunes,Patricia Procter,Nicasio Mancini,Massimo Clementi,Antonella Bisio,Nicholas R. Forsyth,Vito Ferro,Jeremy E. Turnbull,Marco Guerrini,David G. Fernig,Elisa Vicenzi,Edwin A. Yates,Marcelo A. Lima,Mark A. Skidmore

DOI: https://doi.org/10.1055/s-0040-1721319

2020-12-01

Thrombosis and Haemostasis

Abstract:Abstract The dependence of development and homeostasis in animals on the interaction of hundreds of extracellular regulatory proteins with the peri- and extracellular glycosaminoglycan heparan sulfate (HS) is exploited by many microbial pathogens as a means of adherence and invasion. Heparin, a widely used anticoagulant drug, is structurally similar to HS and is a common experimental proxy. Exogenous heparin prevents infection by a range of viruses, including S-associated coronavirus isolate HSR1. Here, we show that heparin inhibits severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) invasion of Vero cells by up to 80% at doses achievable through prophylaxis and, particularly relevant, within the range deliverable by nebulisation. Surface plasmon resonance and circular dichroism spectroscopy demonstrate that heparin and enoxaparin, a low-molecular-weight heparin which is a clinical anticoagulant, bind and induce a conformational change in the spike (S1) protein receptor-binding domain (S1 RBD) of SARS-CoV-2. A library of heparin derivatives and size-defined fragments were used to probe the structural basis of this interaction. Binding to the RBD is more strongly dependent on the presence of 2-O or 6-O sulfate groups than on N-sulfation and a hexasaccharide is the minimum size required for secondary structural changes to be induced in the RBD. It is likely that inhibition of viral infection arises from an overlap between the binding sites of heparin/HS on S1 RBD and that of the angiotensin-converting enzyme 2. The results suggest a route for the rapid development of a first-line therapeutic by repurposing heparin and its derivatives as antiviral agents against SARS-CoV-2 and other members of the Coronaviridae.

peripheral vascular disease,hematology
ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses

Hairui Wang,Shuang Luo,Mingxin Xie,Zhao Chen,Yunming Zhang,Zhiqiang Xie,Yongshun Zhang,Yu Zhang,Lan Yang,Fuhua Wu,Xiaoyan Chen,Guangsheng Du,Jincun Zhao,Xun Sun

DOI: https://doi.org/10.1002/adma.202311537

IF: 29.4

2024-01-06

Advanced Materials

Abstract:A peptide‐modified inhaled nanoemulsions (NEs) are developed, which can target the Angiotensin‐converting enzyme 2 (ACE2) receptor in airway epithelial cells. The inhaled remdesivir NEs inhibit SARS‐CoV‐2 infection and replication. The inhaled drug delivery system loaded with anti‐inflammatory drugs can significantly alleviate the lung tissue injury of mice. Three kinds of coronaviruses are highly pathogenic to humans, and two of them mainly infect humans through Angiotensin‐converting enzyme 2 (ACE2)receptors. Therefore, specifically blocking ACE2 binding at the interface with the receptor‐binding domain is promising to achieve both preventive and therapeutic effects of coronaviruses. Alternatively, drug‐targeted delivery based on ACE2 receptors can further improve the efficacy and safety of inhalation drugs. Here, these two approaches are innovatively combined by designing a nanoemulsion (NE) drug delivery system (termed NE‐AYQ) for inhalation that targets binding to ACE2 receptors. This inhalation‐delivered remdesivir nanoemulsion (termed RDSV‐NE‐AYQ) effectively inhibits the infection of target cells by both wild‐type and mutant viruses. The RDSV‐NE‐AYQ strongly inhibits Severe acute respiratory syndrome coronavirus 2 at two dimensions: they not only block the binding of the virus to host cells at the cell surface but also restrict virus replication intracellularly. Furthermore, in the mouse model of acute lung injury, the inhaled drug delivery system loaded with anti‐inflammatory drugs (TPCA‐1‐NE‐AYQ) can significantly alleviate the lung tissue injury of mice. This smart combination provides a new choice for dealing with possible emergencies in the future and for the rapid development of inhaled drugs for the treatment of respiratory diseases.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment

Nemany A N Hanafy,Maged A El-Kemary

DOI: https://doi.org/10.1016/j.ijbiomac.2021.12.073

2022-02-15

Abstract:Respiratory infected by COVID-19 represents a major global health problem at moment even after recovery from virus corona. Since, the lung lesions for infected patients are still sufferings from acute respiratory distress syndrome including alveolar septal edema, pneumonia, hyperplasia, and hyaline membranes Therefore, there is an urgent need to identify additional candidates having ability to overcome inflammatory process and can enhance efficacy in the treatment of COVID-19. The polypenolic extracts were integrated into moeties of bovine serum albumin (BSA) and then were coated by chitosan as a mucoadhesion polymer. The results of interleukin-6, and c-reactive protein showed significant reduction in group treated by Encap. SIL + CUR (64 ± 0.8 Pg/μL & 6 ± 0.5 μg/μL) compared to group treated by Cham. + CUR (102 ± 0.8 Pg/μL & 7 ± 0.5 μg/μL) respectively and free capsules (with no any drug inside) (148 ± 0.6 Pg/μL & 10 ± 0.6 μg/μL) respectively. Histopathology profile was improved completely. Additionally, encapsulating silymarin showed anti-viral activity in vitro COVID-19 experiment. It can be summarized that muco-inhalable delivery system (MIDS) loaded by silymarin can be used to overcome inflammation induced by oleic acid and to overcome COVID-19.
Patients' and citizens' points of view.

C. Petrini

DOI: https://doi.org/10.1089/bio.2010.0030

2011-06-30

Biopreservation and Biobanking

Abstract:In this article, the first section introduces general considerations on the opinions of patients and the public regarding biobanks. The notion of "public opinion" is briefly described and discussed in a historical perspective. The second section illustrates the results of some surveys carried out in the United States and Europe regarding biobanks. Finally, patients' and citizens' opinions on the storage and use of biological samples are discussed within an ethical framework of principles and values. Four main aspects are discussed: willingness to participate in research; preferences and the perception of norms; language; and opportunities and limits of deliberative democracy in political decisions about biobanking.

Leukotrienes increase levels of prostanoids in cerebrospinal fluid in piglets.

The determination of mercury in water samples from the environment by neutron activation analysis.

Writing to be searched: A workshop on document creation principles

Azithromycin in viral infections

Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function&nbsp;in Patients with Covid-19 Pneumonia

Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin

Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial

Promising Antiviral Activity of Agrimonia pilosa Phytochemicals against Severe Acute Respiratory Syndrome Coronavirus 2 Supported with In Vivo Mice Study

Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19

Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections

Using the StarT Back Tool: Does timing of stratification matter - In response to Peter Kent and Alice Kongsted.

Inhalable Chitosan-Based Hydrogel as a Mucosal Adjuvant for Hydroxychloroquine in the Treatment for SARS-CoV-2 Infection in a Hamster Model

Local Delivery of Azithromycin Nanoformulation Attenuated Acute Lung Injury in Mice

Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment

Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic

Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin

ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses

Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment

Patients' and citizens' points of view.

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function in Patients with Covid-19 Pneumonia